Leishmaniases are vector-borne diseases. Cutaneous leishmaniasis (CL) is endemic in West Africa. Sporadic and anecdotal cases of visceral leishmaniasis (VL) have been reported in the past. Recent data showed the changing of epidemiology of leishmaniases in West Africa, with the occurrence of outbreak of CL due to Leishmania major in urban and rural areas. CL is transmitted by Phlebotomus duboscqi. The role of Sergentomyia (Spelaeomyia) darlingi as vector in rural areas has been evoked but not confirmed. Cases of VL due to Leishmania spp. have been described in West Africa; however, parasites species were not identified and dogs were suspected to be the reservoir. No humans’ case of symptomatic VL due to L. infantum has been described in West Africa. Recent data in rural areas of Senegal confirmed dog as reservoir of L. infantum. In the same study in Senegal, Sergentomyia sandflies were found infected with L. infantum, indicating a possible role in leishmaniasis transmission. Coinfection leishmaniases-HIV is reported but rare. In this chapter, we included most recent publications and propose an updated landscape of CL and VL epidemiology in West Africa.
- West Africa
Leishmaniases are anthropozoonoses common in animals and humans. Leishmaniases are endemics in 98 countries. The annual incidence is 0.7–1.2 million cases of cutaneous leishmaniasis (CL) and 0.2–0.4 million of cases of visceral leishmaniasis (VL) causing 20,000–40,000 deaths annually . In sub-Saharan African region, the estimated annual incidence of CL was between 770 and 1500 cases.
2. Burden and characteristics
2.1. Cutaneous leishmaniasis
The overall burden of CL is poorly characterized, due mainly to paucity of data. The frequency of CL in suspected patients was 78.4% in Mali , and Niger it was 66.7% . In Burkina Faso, CL was perceived as a public health problem due to occurrence of outbreaks with an average incidence of 0.1%  and hospital frequency of 1.1% . In Senegal, the frequency of CL in hospital based study was 38 cases over 4 years (9.5 cases per year) .
In Mali, recent positive LST survey showed a higher prevalence (49.9%) in Diema, Kayes region . LST prevalence in Kayes was 25.7% in 1969 . This difference in LST prevalence in the region of Kayes over a period of more than 45 years is likely to indicate an increasing trend in CL transmission.
Recent findings revealed
The enzymes electrophoresis analysis identified several strains of
In West African countries (Figure 1), CL outbreaks may occur in rural areas where health care centers personnel are not well trained for diagnosis or case management. Often, an investigation post-outbreak is conducted to determine the
Coinfection CL-HIV is rare in West Africa. In Mali, the frequency of coinfection was 1% . Coinfection CL-HIV has been reported in Burkina Faso and Ghana [32, 33]. In patients with coinfection, diffuse CL, mucosal involvement and bone marrow invasion have been reported [16, 34, 35, 36].
2.2. Visceral leishmaniasis
In West Africa, VL has been described, and previous data have shown the scarcity of disease (Figure 1). For several years, anecdotal and sporadic cases of VL were reported. Up to today, the data reviewed identified most of the clinical cases of VL in Ivory Coast and Niger [6, 7, 8]. In the Gambia, a case of VL has been reported in humans and in dogs [37, 38]. Underreporting of diseases is a known feature of West African health care system. This is also true for VL. The underreporting of VL in West Africa could be favored by the absence of appropriate biological diagnosis and the absence of specificity of VL clinical symptoms. VL cases may be confounded with others frequent parasitic diseases such as malaria or schistosomiasis. It is also assumed that the parasite strains found in West Africa are less virulent than those found elsewhere (Asia and East Africa). The strain identified in Senegal and likely those in West Africa are coming from Mediterranean basin .
Parasite species identified in West Africa is
Sandflies of the genus
3. Management and control
VL is rarely encountered in West Africa. Most cases of human Leishmaniasis are cutaneous leishmaniasis. Often, CL cases are under-diagnosed, and their clinical management is poorly done. This is particularly true for cases encountered at peripheral health care centers with personnel poorly trained. For those encountered at referral health care facilities with good capacity for the diagnosis, treatment is available. In Mali, CL cases are referred to National Center for Diseases Control [CNAM acronym in French for Centre National d’Appui à Lutte contre la Maladie]. Treatment is done using either meglumine antimoniate locally or local thermotherapy . In Burkina Faso, meglumine antimoniate is the first line treatment . Treatment outcome is favorable with healing of lesions in 2–4 weeks. Treatment response in HIV coinfected patients is also favorable but hampered by the frequency of relapses .
In rural areas where these treatments are not available dermatologists advice to clean skin lesions and apply tetracycline ointment until healing . Meglumine antimoniate and amphotericin B have been used to treat VL in West Africa [6, 7, 8].
Compared to other endemic parts of the world, leishmaniases are not very common in West Africa. CL is widely distributed in few West African countries such as Burkina Faso, Mali, Nigeria and Senegal. Urbanization is the main risk factor. Human VL human is sporadic in few countries. Also, VL affects more domestic dogs. Our review acknowledged the changing of CL epidemiology with more report of outbreaks and description of new parasite species in West Africa. A surveillance system based on referral health care centers with training of health care personnel will help to better address clinical and diagnostic challenges imposed by leishmaniasis.
Conflict of interest
No conflict of interest declared.